CATALIST-listed AOXIN Q&M records 21% growth in revenue for full year ended 31 December 2021
- EBITDA grew 47% for 12 months ended 31 Dec 2021- Proposed listing of 49%-owned Acumen Diagnostics on NASDAQ will enhance AOXIN's shareholder value- Growth trend in revenue expected to continue as COVID-19